Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993212 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| SCHEMBL1581048 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| Hydrochloric Acid SCHEMBL4284338 | 0.98 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| 2-Chloropyridine SCHEMBL6248567 | 0.89 | TDP1 (0.55) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| SCHEMBL3224199 | 0.85 | HRH1 (0.45) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| Hydrochloric Acid SCHEMBL5846124 | 0.83 | HRH1 (0.44) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| Hydrochloric Acid SCHEMBL28631671 | 0.83 | HRH1 (0.44) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| SCHEMBL24099467 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| SCHEMBL3388486 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D | |
| SCHEMBL311511 | 0.81 | KCNA5 (0.50) | SLC6A2SLC6A4SLC6A3TSHRGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3448389-B1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | SLC6A2 275/4885SLC6A4 251/4885SLC6A3 669/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | SLC6A2 275/4885SLC6A4 251/4885SLC6A3 669/4885 |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | SLC6A2 4305/4885SLC6A4 4200/4885SLC6A3 3260/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | SLC6A2 275/4885SLC6A4 251/4885SLC6A3 669/4885 |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | SLC6A2 275/4885SLC6A4 251/4885SLC6A3 669/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | SLC6A2 275/4885SLC6A4 251/4885SLC6A3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.